Medicare prescription drug cost, prescriptions and prescribers, 2024
Medicare cost, 2024
$127.7M
-26.1% from 2023
Prescriptions
58K
$2,219.06 per claim
Patients
9,122
4,801 prescribers
Total spending, 2024
$127.6M
$13,993.11 per patient
Medicare prescription drug plans paid $127.7M for Pirfenidone in 2024, for 57,542 prescriptions and refills to 9,122 patients (down 26.1% from 2023). The average cost per claim was $2,219.06.
Texas had the highest Medicare cost for Pirfenidone in 2024: $11.0M for 4,267 claims, followed by New York ($10.5M).
Girish Nair, pulmonary disease in Lexington, KY, had the highest Medicare cost for Pirfenidone in 2024: 141 claims costing $689K.
All plans and makers
Where the prescribers practice, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Girish Nair Lexington, KY | Pulmonary Disease | 141 | 20 | $689K |
| Kevin R Flaherty Ann Arbor, MI | Pulmonary Disease | 168 | 28 | $600K |
| Jessica Glennie |
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 3,204 | 23,782 | 5,308 | $136.8M |
| 2023 | 4,303 | 48,765 | 7,773 | $172.7M |
| 2024 | 4,801 | 57,542 | 9,122 | $127.7M |
Amount reimbursed by state Medicaid programs, all states
More drugs: top Medicare drugs by cost and the Prescriptions tab.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
| Nurse Practitioner |
| 174 |
| 23 |
| $541K |
| Shelley L Schmidt Grand Rapids, MI | Pulmonary Disease | 114 | 14 | $502K |
| Traci N Adams Dallas, TX | Pulmonary Disease | 159 | 30 | $501K |
| Tracy J Doyle Boston, MA | Pulmonary Disease | 90 | 14 | $454K |
| Aman Pande Westlake, OH | Pulmonary Disease | 124 | 16 | $448K |
| Robby T Ayoub Huntington Beach, CA | Internal Medicine | 70 | Under 11 | $408K |
| David L Miller Boston, MA | Pulmonary Disease | 45 | Under 11 | $365K |
| Rodeo A Abrencillo Houston, TX | Critical Care (Intensivists) | 95 | 15 | $349K |
| Randall C Bell San Antonio, TX | Pulmonary Disease | 73 | 13 | $348K |
| Mary B Scholand Salt Lake City, UT | Pulmonary Disease | 263 | 41 | $346K |
| Jisha K Joshua San Diego, CA | Pulmonary Disease | 113 | 17 | $346K |
| Erica A Ludtke Nashville, TN | Nurse Practitioner | 123 | 24 | $338K |
| Elizabeth A Belloli Ann Arbor, MI | Pulmonary Disease | 165 | 23 | $327K |
| Kelsey Polikowski Boston, MA | Nurse Practitioner | 64 | Under 11 | $295K |
| Yolanda N Mageto Dallas, TX | Pulmonary Disease | 88 | 11 | $295K |
| Shannon Benesh New York, NY | Nurse Practitioner | 77 | 13 | $292K |
| Rachana Krishna Charleston, SC | Pulmonary Disease | 72 | 14 | $284K |
| Leslie B Tolle Cleveland, OH | Pulmonary Disease | 100 | 15 | $283K |
| Angela M Dimango New York, NY | Pulmonary Disease | 54 | Under 11 | $280K |
| Mark W Johnson Lubbock, TX | Pulmonary Disease | 52 | Under 11 | $278K |
| Eric A Crawley Honolulu, HI | Critical Care (Intensivists) | 34 | Under 11 | $277K |
| Marta Kokoszynska-Werner Burlington, VT | Pulmonary Disease | 74 | 11 | $275K |
| Apostolos Perelas Richmond, VA | Pulmonary Disease | 202 | 40 | $271K |
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Laurus Labs Lim LAURUSLABS.NS | 17,980 | $36.0M |
| Cipla USA, Inc. CIPLA.NS | 9,822 | $34.2M |
| Novadoz Pharmac | 5,189 | $15.3M |
| Amneal Pharmace AMRX | 7,655 | $13.9M |
| Sandoz SDZ.SW | 2,837 | $7.2M |
| Alembic Pharmac | 3,444 | $7.2M |
| Camber Pharmace | 4,537 | $6.8M |
| Teva USA TEVA | 5,580 | $6.2M |
| Northstar Rx Ll | 478 | $808K |